Allakos LLC, formerly known as Allakos Inc. is a biotechnology company. The Company is developing therapeutics that target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory and proliferative diseases.

Employees

Sector

Biotechnology & Medical Research

More about the company

Income Statement and Estimates

More financial data

Market Closed - Nasdaq Other stock markets 16:00:00 2025-05-14 EDT			5-day change	1st Jan Change
0.3291 ^USD	-0.06%		-.--%	-

25-05-15	Allakos Inc. Announces Resignation of Dr. Robert Alexander as CEO	CI
25-05-15	Allakos Inc. Announces Resignation of Baird Radford as CFO	CI

Market Cap	29.74M 25.66M 23.59M 22.2M 41.72M 2.81B 42.07M 280M 109M 1.38B 112M 109M 4.77B	P/E 2023	-1.28x	P/E 2024	-0.93x
Enterprise Value	-46.92M -40.48M -37.21M -35.03M -65.82M -4.43B -66.37M -441M -172M -2.17B -176M -172M -7.52B	EV / Sales 2023	-	EV / Sales 2024	-
Free-Float	96.57%	Yield 2023 *	-	Yield 2024	-

25-05-15	Allakos Inc. Announces Resignation of Dr. Robert Alexander as CEO	CI
25-05-15	Allakos Inc. Announces Resignation of Baird Radford as CFO	CI
25-05-15	Allakos Inc. Announces Executive Changes	CI
25-05-14	Allakos Inc.(NasdaqGS:ALLK) dropped from NASDAQ Composite Index	CI
25-05-14	Concentra Biosciences, LLC completed the acquisition of Allakos Inc..	CI
25-05-08	Allakos Inc.(NasdaqGS:ALLK) dropped from S&P TMI Index	CI
25-05-07	Allakos Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
25-04-02	Allakos to Be Acquired by Concentra Biosciences for $0.33 per Share	MT
25-04-02	Allakos Inc. Enters Into Agreement To Be Acquired By Concentra Biosciences	RE
25-04-01	Concentra Biosciences, LLC entered into an agreement to acquire Allakos Inc. for $31 million.	CI
25-03-12	Allakos Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024	CI
25-03-12	Allakos Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2024	CI
25-01-27	Top Midday Decliners	MT

24-01-17	Barclays Trims Allakos' Price Target to $1 From $1.50, Maintains Underweight Rating	MT
24-01-17	JMP Securities Adjusts Allakos' Price Target to $3 From $10, Maintains Market Outperform Rating	MT
24-01-17	Jefferies Downgrades Allakos to Hold From Buy, Adjusts Price Target to $1.50 From $6	MT
24-01-16	Cantor Fitzgerald Downgrades Allakos to Neutral From Overweight	MT
24-01-16	Lifesci Capital Downgrades Allakos to Market Perform From Outperform	MT

Allakos Inc. Stock

Stocks

ALLK

US01671P1003

Biotechnology & Medical Research

Valuation: Allakos Inc.

Latest news : Allakos Inc.

Analysts' recommendations: Allakos Inc.

Press Releases: Allakos Inc.

News in other languages: Allakos Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Allakos Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Income Statement and Estimates

22-07-22	Lonza-Aktien sinken nach Halbjahreszahlen
19-12-05	EN DIRECT DES MARCHES : Kering / Moncler, FDJ, Engie, Capgemini, Cybergun, Amazon, Fiat Chrysler...
19-12-05	Des marchés moins cyclothymiques pour finir la semaine ?

Date	Insider	Type	Main position	Quantity	% Market Cap.
25-05-14	Dolca Thomas	Issuer sale	Director	195,786	0.2191%
25-05-14	Neil Graham	Issuer sale	Director	195,786	0.2191%
25-05-14	BVF Partners LP	Issuer sale	Company	16,312,872	18.2586%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ALLAKOS INC.	-0.06%	-.--%	-.--%	-92.94%	29.74M
LONZA GROUP AG	-0.22%	-1.14%	-11.88%	-13.09%	43.51B
REVOLUTION MEDICINES, INC.	+0.76%	+9.42%	+303.09%	+540.82%	33.29B
IQVIA HOLDINGS INC.	-4.74%	-6.31%	+10.75%	-20.99%	29.9B
BEONE MEDICINES AG	-0.47%	-0.35%	+3.38%	+31.20%	29.34B
CELLTRION, INC.	+0.06%	+4.36%	+13.31%	+21.11%	25.42B
ASCENDIS PHARMA A/S	-0.02%	+10.18%	-	-	14.36B
MEDPACE HOLDINGS, INC.	-0.98%	-1.86%	+53.43%	+106.06%	13.18B
EUROFINS SCIENTIFIC SE	-0.29%	-4.40%	+3.13%	+1.69%	12.72B
IONIS PHARMACEUTICALS, INC.	+1.67%	+1.35%	+105.56%	+81.16%	12.08B
Average	-0.43%	+1.44%	+53.42%	+72.78%	21.38B
Weighted average by Cap.	-0.63%	+1.76%	+61.92%	+103.55%

	2023	2024
Net sales	-	-
Net income	-186M -160M -147M -139M -261M -17.53B -263M -1.75B -680M -8.6B -697M -682M -29.76B	-116M -99.92M -91.86M -86.46M -162M -10.93B -164M -1.09B -424M -5.36B -435M -425M -18.56B
Net Debt	-129M -112M -103M -96.55M -181M -12.21B -183M -1.22B -473M -5.99B -485M -475M -20.72B	-76.66M -66.14M -60.8M -57.23M -108M -7.23B -108M -721M -281M -3.55B -288M -282M -12.28B

3 years	0.22	5.64
5 years	0.22	112.87
10 years	0.22	157.98